[An evaluation of the therapeutic trials aimed at regression of ventricular hypertrophy in arterial hypertension].
Left ventricular hypertrophy (LVH) which is a mechanism of adaptation of the heart to hypertension (HT) may become a cardiovascular risk factor independent of the HT which has caused it. Causing the regression of LVH is thus one of the mid-term aims of antihypertensive therapy. Certain antihypertensive drugs are capable of producing an early and durable regression of LVH: methyldopa, beta-blockers, ACEI, calcium blockers. The effect of mass reduction is moderate or doubtful with diuretics, while it is nil or inconstant with vasodilators. The regression of LVH in HT raises various problems: 1) reliability of the measurement technique, 2) inter-individual and inter-drug variations, 3) favourable nature of regression, 4) preventive effect of regression against cardiovascular complications. Finally, in the light of recent studies it appears that early treatment of HT may prevent the onset of LVH.
Clémenty
J
J
Hôpital Cardiologique, Université de Bordeaux, Pessac.
Dulhoste
M N
MN
Bordier
P
P
Lartigue
M C
MC
Pons
N
N
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D013997:Time Factors
D000959:Antihypertensive Agents
Bilan des essais thérapeutiques visant à faire régresser l'hypertrophie ventriculaire gauche dans l'hypertension artérielle.